


# Macedonia

Factor VIII per capita compared to other countries

This country fact sheet accompanies the EHC heat map and gives you further information on the country's progress over the various EHC surveys.

Here, you will see how the FVIII international units provision has evolved and compares to other countries. You will also find the same parameters as in the heat map.



Change since previous survey: ▲ Improvement ▼ Decline

		2009	2012	2015	2018
International units per capita	Factor VIII	0.00	▲ 1.75	▲ 2.89	▼ 2.88
	Factor IX	0.00	▲ 0.46	▲ 0.96	▼ 0.48
Organisation of care	Comprehensive Care Centres (CCC's)	No	No	No	▲ Yes
	Haemophilia Treatment Centres	Yes	Yes	Yes	Yes
	National Haemophilia Council or Co-ordinating Group	No	No	▲ Yes	Yes
	Number of groups in decision-making on haemophilia care	2	2	2	2
	Number of groups choosing haemophilia treatment products	2	2	2	2
	National Tender for procurement of factor concentrates		Yes	Yes	Yes
Treatment regimens	Home Treatment	Yes	Yes	Yes	Yes
	% of people with haemophilia using home treatment		76-100%	76-100%	76-100%
	Treatment delivered to the patient's home		No	No	No
	Prophylaxis treatment availability		Some	Some	Some
	Children currently on prophylaxis (%)		76-100%	76-100%	76-100%
	Adults currently on prophylaxis (%)		1-25%	1-25%	1-25%
Access to specialist services	Access to ITI (% of people with inhibitors)	0	0	0	0
Access to specialist services	Emergency medicine and acute surgery			Yes	Yes
	Paediatrics		Yes	Yes	Yes
	Infectious disease specialists (especially HIV)		Sometimes	▲ Yes	▼ Sometimes
	Hepatology		Sometimes	▲ Yes	▼ Sometimes
	Rheumatology		Sometimes	▼ Never	Never
	Orthopaedics		Yes	Yes	Yes
	Physiotherapy		Yes	Yes	Yes
	Dentistry		Yes	Yes	Yes
	Obstetrics and Gynaecology		Yes	Yes	Yes
	Genetics		Sometimes	▲ Yes	Yes
	Social and psychological support		Never	▲ Yes	Yes
	Pain management		Never	▲ Sometimes	▼ Never
	General surgery		Never	▲ Yes	Yes
Urology		Never	▲ Never	▲ Sometimes	
Share of Expected Bleeding Disorder Prevalence	Haemophilia A		101%	▲ 102%	▼ 99%
	Haemophilia B		167%	▲ 170%	▲ 171%
	von Willebrand Disease			10%	▼ 8%
Haemophilia replacement therapy	Plasma-derived factor concentrate	Rarely	▲ Always	Always	Always
	Recombinant factor concentrate	Rarely	▲ Rarely	Rarely	Rarely
	Plasma		Never	Never	Never
	Cryoprecipitate	Always	▲ Never	Never	Never
VWD replacement therapy	Plasma-derived factor concentrate		Rarely	▼ Never	▲ Rarely
	DDAVP		Never	Never	Never
	Plasma		Always	▲ Rarely	▲ Never
	Cryoprecipitate		Always	Always	Always